综述 |
|
|
|
|
人源性食管癌异种移植模型的建立及应用进展* |
梁帆1,程洪伟1,**(),张俊河1,2,**() |
1.新乡医学院健康中原研究院 新乡 453003 2.新乡医学院生物化学与分子生物学系 新乡 453003 |
|
Establishment and Application Progress of Patient-derived Xenograft Model of Esophageal Cancer |
LIANG Fan1,CHENG Hong-wei1,**(),ZHANG Jun-he1,2,**() |
1. Institutes of Health Central Plains, Xinxiang Medical University, Xinxiang 453003, China 2. Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, China |
[1] |
Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
doi: 10.3322/caac.21660
|
[2] |
Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surgery Today, 2020, 50(1): 12-20.
doi: 10.1007/s00595-019-01878-7
|
[3] |
Huang F L, Yu S J. Esophageal cancer: risk factors, genetic association, and treatment. Asian Journal of Surgery, 2018, 41(3): 210-215.
doi: 10.1016/j.asjsur.2016.10.005
|
[4] |
Rustgi A K, El-Serag H B. Esophageal carcinoma. The New England Journal of Medicine, 2014, 371(26): 2499-2509.
doi: 10.1056/NEJMra1314530
pmid: 25539106
|
[5] |
Shi M C, Wang Y, Lin D, et al. Patient-derived xenograft models of neuroendocrine prostate cancer. Cancer Letters, 2022, 525: 160-169.
doi: 10.1016/j.canlet.2021.11.004
|
[6] |
Meehan T F. Know thy PDX model. Cancer Research, 2019, 79(17): 4324-4325.
|
[7] |
Fujii E, Kato A, Suzuki M. Patient-derived xenograft (PDX) models: characteristics and points to consider for the process of establishment. Journal of Toxicologic Pathology, 2020, 33(3): 153-160.
doi: 10.1293/tox.2020-0007
|
[8] |
Abdolahi S, Ghazvinian Z, Muhammadnejad S, et al. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. Journal of Translational Medicine, 2022, 20(1): 206.
doi: 10.1186/s12967-022-03405-8
|
[9] |
Saw P E, Chen J N, Song E W. Targeting CAFs to overcome anticancer therapeutic resistance. Trends in Cancer, 2022, 8(7): 527-555.
doi: 10.1016/j.trecan.2022.03.001
|
[10] |
Cho S Y, Kang W, Han J Y, et al. An integrative approach to precision cancer medicine using patient-derived xenografts. Molecules and Cells, 2016, 39(2): 77-86.
doi: 10.14348/molcells.2016.2350
|
[11] |
Sia D, Moeini A, Labgaa I, et al. The future of patient-derived tumor xenografts in cancer treatment. Pharmacogenomics, 2015, 16(14): 1671-1683.
doi: 10.2217/pgs.15.102
|
[12] |
Dobbin Z C, Katre A A, Steg A D, et al. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget, 2014, 5(18): 8750-8764.
doi: 10.18632/oncotarget.2373
|
[13] |
Lohse I, Borgida A, Cao P, et al. BRCA1 and BRCA 2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. British Journal of Cancer, 2015, 113(3): 425-432.
doi: 10.1038/bjc.2015.220
pmid: 26180923
|
[14] |
Lai Y X, Wei X R, Lin S H, et al. Current status and perspectives of patient-derived xenograft models in cancer research. Journal of Hematology & Oncology, 2017, 10(1): 106.
|
[15] |
Okada S, Vaeteewoottacharn K, Kariya R. Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models. Cells, 2019, 8(8): 889.
doi: 10.3390/cells8080889
|
[16] |
Flanagan S P. ‘Nude’, a new hairless gene with pleiotropic effects in the mouse. Genetical Research, 1966, 8(3): 295-309.
doi: 10.1017/S0016672300010168
|
[17] |
李晓娟, 冯帆, 李瑞生, 等. 肝细胞癌人源异种移植模型应用研究进展. 传染病信息, 2021, 34(3): 202-207, 217.
|
|
Li X J, Feng F, Li R S, et al. Advances in application of patient-derived xenograft model for hepatocellular carcinoma. Infectious Disease Information, 2021, 34(3): 202-207, 217.
|
[18] |
Pan B H, Wei X Y, Xu X. Patient-derived xenograft models in hepatopancreatobiliary cancer. Cancer Cell International, 2022, 22(1): 41.
doi: 10.1186/s12935-022-02454-9
|
[19] |
Giovanella B C, Fogh J. The nude mouse in cancer research. Advances in Cancer Research, 1985, 44: 69-120.
pmid: 3898740
|
[20] |
Bosma G C, Custer R P, Bosma M J. A severe combined immunodeficiency mutation in the mouse. Nature, 1983, 301(5900): 527-530.
doi: 10.1038/301527a0
|
[21] |
张楠楠, 卢荣梦, 孟廷薪. 免疫缺陷动物模型研究进展. 华南国防医学杂志, 2021, 35(7): 541-545.
|
|
Zhang N N, Lu R M, Meng T X. Research progress of immunodeficiency animal model. Military Medical Journal of South China, 2021, 35(7): 541-545.
|
[22] |
Makino S, Kunimoto K, Muraoka Y, et al. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu Experimental Animals, 1980, 29(1): 1-13.
pmid: 6995140
|
[23] |
Kikutani H, Makino S. The murine autoimmune diabetes model: nod and related strains. Advances in Immunology, 1992, 51: 285-322.
pmid: 1323922
|
[24] |
Shultz L D, Schweitzer P A, Christianson S W, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. Journal of Immunology (Baltimore, Md: 1950), 1995, 154(1): 180-191.
|
[25] |
Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/gammac(null)mouse: an excellent recipient mouse model for engraftment of human cells. Blood, 2002, 100(9): 3175-3182.
doi: 10.1182/blood-2001-12-0207
|
[26] |
McDermott S P, Eppert K, Lechman E R, et al. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood, 2010, 116(2): 193-200.
doi: 10.1182/blood-2010-02-271841
pmid: 20404133
|
[27] |
Nagatani M, Kodera T, Suzuki D, et al. Comparison of biological features between severely immuno-deficient NOD/Shi-scid Il2rg null and NOD/LtSz-scid Il2rg null mice. Experimental Animals, 2019, 68(4): 471-482.
doi: 10.1538/expanim.19-0024
pmid: 31118345
|
[28] |
李媛, 闫平. 免疫缺陷小鼠平台上的人肿瘤异种移植研究进展. 武汉大学学报(医学版), 2012, 33(1): 137-140.
|
|
Li Y, Yan P. Advances of patient-derived human tumor tissue xenografts research in immunodeficient mice. Medical Journal of Wuhan University, 2012, 33(1): 137-140.
|
[29] |
Shin H Y, Lee E J, Yang W, et al. Identification of prognostic markers of gynecologic cancers utilizing patient-derived xenograft mouse models. Cancers, 2022, 14(3): 829.
doi: 10.3390/cancers14030829
|
[30] |
Jung J, Seol H S, Chang S. The generation and application of patient-derived xenograft model for cancer research. Cancer Research and Treatment, 2018, 50(1): 1-10.
doi: 10.4143/crt.2017.307
|
[31] |
Veeranki O L, Tong Z M, Mejia A, et al. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Disease Models & Mechanisms, 2019, 12(12): dmm041004.
|
[32] |
Lan T F, Xue X, Dunmall L C, et al. Patient-derived xenograft: a developing tool for screening biomarkers and potential therapeutic targets for human esophageal cancers. Aging (Albany NY), 2021, 13(8): 12273-12293.
|
[33] |
管柳柳, 邹晴晴, 刘倩, 等. 食管鳞癌患者来源移植瘤模型: B-NDG(R)小鼠与BALB/c裸鼠的比较. 南方医科大学学报, 2020, 40(8): 1200-1206.
|
|
Guan L L, Zou Q Q, Liu Q, et al. Comparison of B-NDG(R) and BALB/c mouse models bearing patient-derived xenografts of esophageal squamous cell carcinoma. Journal of Southern Medical University, 2020, 40(8): 1200-1206.
|
[34] |
Fujii E, Kato A, Chen Y J, et al. Characterization of EBV-related lymphoproliferative lesions arising in donor lymphocytes of transplanted human tumor tissues in the NOG mouse. Experimental Animals, 2014, 63(3): 289-296.
doi: 10.1538/expanim.63.289
|
[35] |
Tse E, Kwong Y L. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Experimental & Molecular Medicine, 2015, 47(1): e136.
|
[36] |
Kanda T R, Yajima M, Ikuta K. Epstein-Barr virus strain variation and cancer. Cancer Science, 2019, 110(4): 1132-1139.
doi: 10.1111/cas.13954
pmid: 30697862
|
[37] |
Fujii E, Kato A, Chen Y J, et al. The status of donor cancer tissues affects the fate of patient-derived colorectal cancer xenografts in NOG mice. Experimental Animals, 2015, 64(2): 181-190.
doi: 10.1538/expanim.14-0080
|
[38] |
Read M, Liu D, Duong C P, et al. Intramuscular transplantation improves engraftment rates for esophageal patient-derived tumor xenografts. Annals of Surgical Oncology, 2016, 23(1): 305-311.
doi: 10.1245/s10434-015-4425-3
|
[39] |
Cutz J C, Guan J, Bayani J, et al. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clinical Cancer Research, 2006, 12(13): 4043-4054.
doi: 10.1158/1078-0432.CCR-06-0252
|
[40] |
Huang P G, Westmoreland S V, Jain R K, et al. Spontaneous nonthymic tumors in SCID mice. Comparative Medicine, 2011, 61(3): 227-234.
|
[41] |
Santagostino S F, Arbona R, Nashat M A, et al. Pathology of aging in NOD scid gamma female mice. Veterinary Pathology, 2017, 54(5): 855-869.
doi: 10.1177/0300985817698210
pmid: 28355107
|
[42] |
Plaks V, Kong N W, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell, 2015, 16(3): 225-238.
doi: 10.1016/j.stem.2015.02.015
|
[43] |
Liu Z C, Wu K Q, Gu S R, et al. A methyltransferase-like 14/miR-99a-5p/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radioresistance via histone deacetylase 2-mediated epigenetic modulation in esophageal squamous cell carcinoma. Clinical and Translational Medicine, 2021, 11(9): e545.
|
[44] |
Liu D S H, Read M, Cullinane C, et al. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. Gut, 2015, 64(10): 1506-1516.
doi: 10.1136/gutjnl-2015-309770
|
[45] |
Zhang C J, Zhang J X, Wu Q, et al. Sulforaphene induces apoptosis and inhibits the invasion of esophageal cancer cells through MSK2/CREB/Bcl-2 and cadherin pathway in vivo and in vitro. Cancer Cell International, 2019, 19: 342.
doi: 10.1186/s12935-019-1061-1
|
[46] |
Talukdar A, Kundu B, Sarkar D, et al. Topoisomerase I inhibitors: Challenges, progress and the road ahead. European Journal of Medicinal Chemistry, 2022, 236: 114304.
doi: 10.1016/j.ejmech.2022.114304
|
[47] |
Wu J H, Phatnani H P, Hsieh T S, et al. The phosphoCTD-interacting domain of topoisomerase I. Biochemical and Biophysical Research Communications, 2010, 397(1): 117-119.
doi: 10.1016/j.bbrc.2010.05.081
|
[48] |
Pommier Y, Sun Y L, Huang S Y N, et al. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nature Reviews Molecular Cell Biology, 2016, 17(11): 703-721.
doi: 10.1038/nrm.2016.111
pmid: 27649880
|
[49] |
Hanagiri T, Ono K, Kuwata T, et al. Evaluation of topoisomerase I/topoisomerase IIalpha status in esophageal cancer. Journal of UOEH, 2011, 33(3): 205-216.
pmid: 21913377
|
[50] |
Mohinudeen I A H K, Kanumuri R, Soujanya K N, et al. Sustainable production of camptothecin from an Alternaria sp. isolated from Nothapodytes nimmoniana. Scientific Reports, 2021, 11: 1478.
doi: 10.1038/s41598-020-79239-5
pmid: 33446714
|
[51] |
Hsiang Y H, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. The Journal of Biological Chemistry, 1985, 260(27): 14873-14878.
doi: 10.1016/S0021-9258(17)38654-4
|
[52] |
Zou J L, Li S, Chen Z H, et al. A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo. Cell Death & Disease, 2018, 9: 661.
|
[53] |
Song M Q, Yin S Y, Zhao R, et al. (S)-10-hydroxycamptothecin inhibits esophageal squamous cell carcinoma growth in vitro and in vivo via decreasing topoisomerase I enzyme activity. Cancers, 2019, 11(12): 1964.
doi: 10.3390/cancers11121964
|
[54] |
Hynes R O. Integrins: bidirectional, allosteric signaling machines. Cell, 2002, 110(6): 673-687.
doi: 10.1016/S0092-8674(02)00971-6
|
[55] |
Fan Z, Chang Y, Cui C C, et al. Near infrared fluorescent peptide nanoparticles for enhancing esophageal cancer therapeutic efficacy. Nature Communications, 2018, 9: 2605.
doi: 10.1038/s41467-018-04763-y
|
[56] |
Hussain M, le Moulec S, Gimmi C, et al. Differential effect on bone lesions of targeting integrins: randomized phase II trial of abituzumab in patients with metastatic castration-resistant prostate cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2016, 22(13): 3192-3200.
doi: 10.1158/1078-0432.CCR-15-2512
|
[57] |
Vane J, Botting R. Mechanism of action of antiinflammatory drugs. Adv Exp Med Biol, 1997, 433:131-138.
pmid: 9561120
|
[58] |
Liu F F, Wu Q, Han W, et al. Targeting integrin αvβ 3 with indomethacin inhibits patient-derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma. Clinical and Translational Medicine, 2021, 11(10): e548.
|
[59] |
He S M, Zhao C Y, Tao H Y, et al. A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH 2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer. Drug Delivery, 2022, 29(1): 1243-1256.
doi: 10.1080/10717544.2022.2063454
|
[60] |
Zhu H T, Wang C Y, Wang J J, et al. A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification. Journal of Thoracic Disease, 2018, 10(9): 5328-5338.
doi: 10.21037/jtd.2018.09.18
|
[61] |
Yang Y M, Hong P, Xu W W, et al. Advances in targeted therapy for esophageal cancer. Signal Transduction and Targeted Therapy, 2020, 5: 229.
doi: 10.1038/s41392-020-00323-3
pmid: 33028804
|
[62] |
Ren Y X, Zheng J M, Fan S M, et al. Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification. Oncotarget, 2017, 8(31): 50832-50844.
doi: 10.18632/oncotarget.17243
|
[63] |
Liu Z T, Chen Z H, Wang J Y, et al. Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance. Journal of Hematology & Oncology, 2018, 11(1): 109.
|
[64] |
Chong C R, Jänne P A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nature Medicine, 2013, 19(11): 1389-1400.
doi: 10.1038/nm.3388
|
[65] |
Ebbing E A, Medema J P, Damhofer H, et al. ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3. Oncotarget, 2016, 7(9): 10243-10254.
doi: 10.18632/oncotarget.7200
pmid: 26863569
|
[66] |
Wu X H, Zhang J C, Zhen R H, et al. Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. Journal of Translational Medicine, 2012, 10: 180.
doi: 10.1186/1479-5876-10-180
|
[67] |
Zhang J C, Jiang D X, Li X J, et al. Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. Laboratory Investigation, 2014, 94(8): 917-926.
doi: 10.1038/labinvest.2014.77
|
[68] |
Hou W M, Qin X, Zhu X H, et al. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. Oncology Reports, 2013, 30(2): 707-714.
doi: 10.3892/or.2013.2500
|
[69] |
Pahl R, Brunke G, Steubesand N, et al. IL-1β and ADAM 17 are central regulators of β-defensin expression in Candida esophagitis. American Journal of Physiology Gastrointestinal and Liver Physiology, 2011, 300(4): G547-G553.
doi: 10.1152/ajpgi.00251.2010
|
[70] |
Liu H B, Zhu Y, Yang Q C, et al. Expression and clinical significance of ADAM 17 protein in esophageal squamous cell carcinoma. Genetics and Molecular Research: GMR, 2015, 14(2): 4391-4398.
doi: 10.4238/2015.April.30.12
|
[71] |
Gao L, Liu H, Xu R, et al. ADAM17 and NF-kappaB p 65 form a positive feedback loop that facilitates human esophageal squamous cell carcinoma cell viability. Int J Clin Exp Pathol, 2021, 14(7):845-854.
|
[72] |
Rios-Doria J, Sabol D, Chesebrough J, et al. A monoclonal antibody to ADAM 17 inhibits tumor growth by inhibiting EGFR and non-EGFR-mediated pathways. Molecular Cancer Therapeutics, 2015, 14(7): 1637-1649.
doi: 10.1158/1535-7163.MCT-14-1040
pmid: 25948294
|
[73] |
Nishigaki T, Takahashi T, Serada S, et al. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. British Journal of Cancer, 2020, 122(9): 1333-1341.
doi: 10.1038/s41416-020-0781-2
pmid: 32152502
|
[74] |
Li J, Chen Y J, Zhan C, et al. Glypican-1 promotes tumorigenesis by regulating the PTEN/Akt/β-catenin signaling pathway in esophageal squamous cell carcinoma. Digestive Diseases and Sciences, 2019, 64(6): 1493-1502.
doi: 10.1007/s10620-019-5461-9
|
[75] |
Hara H, Takahashi T, Serada S, et al. Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma. British Journal of Cancer, 2016, 115(1): 66-75.
doi: 10.1038/bjc.2016.183
|
[76] |
Harada E, Serada S, Fujimoto M, et al. Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma. Oncotarget, 2017, 8(15): 24741-24752.
doi: 10.18632/oncotarget.15799
pmid: 28445969
|
[77] |
Birrer M J, Moore K N, Betella I, et al. Antibody-drug conjugate-based therapeutics: state of the science. JNCI: Journal of the National Cancer Institute, 2019, 111(6): 538-549.
doi: 10.1093/jnci/djz035
|
[78] |
Munekage E, Serada S, Tsujii S, et al. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. Neoplasia, 2021, 23(9): 939-950.
doi: 10.1016/j.neo.2021.07.006
pmid: 34332450
|
[79] |
Apicella M, Migliore C, Capelôa T, et al. Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort. Oncogene, 2017, 36(9): 1200-1210.
doi: 10.1038/onc.2016.283
pmid: 27524418
|
[80] |
Liu J, Liu Z X, Wu Q N, et al. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nature Communications, 2020, 11: 1507.
doi: 10.1038/s41467-020-15112-3
|
[81] |
Sugase T, Takahashi T, Serada S, et al. Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice. International Journal of Cancer, 2017, 140(11): 2608-2621.
doi: 10.1002/ijc.30666
|
[82] |
Liu X J, Song M Q, Wang P L, et al. Targeted therapy of the AKT kinase inhibits esophageal squamous cell carcinoma growth in vitro and in vivo. International Journal of Cancer, 2019, 145(4): 1007-1019.
doi: 10.1002/ijc.32285
|
[83] |
Liu A B, Zhu J R, Wu G Y, et al. Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma. Molecular Cancer, 2017, 16(1): 106.
doi: 10.1186/s12943-017-0669-9
|
[84] |
Mizumoto A, Ohashi S, Kamada M, et al. Combination treatment with highly bioavailable curcumin and NQO 1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma. Journal of Gastroenterology, 2019, 54(8): 687-698.
doi: 10.1007/s00535-019-01549-x
pmid: 30737573
|
[85] |
张琪琪, 刘清, 郑树涛, 等. NSC74859对食管鳞状细胞癌人源肿瘤异种移植模型的抗肿瘤作用研究. 新疆医科大学学报, 2021, 44(5): 528-533.
|
|
Zhang Q Q, Liu Q, Zheng S T, et al. Antitumor effect of NSC 74859 on patient-derived tumor xenograft of esophageal squamous cell carcinoma. Journal of Xinjiang Medical University, 2021, 44(5): 528-533.
|
[86] |
Zhang Z F, Zhang C Y, Miao J X, et al. A tumor-targeted replicating oncolytic adenovirus ad-TD-nsIL 12 as a promising therapeutic agent for human esophageal squamous cell carcinoma. Cells, 2020, 9(11): 2438.
doi: 10.3390/cells9112438
|
[87] |
Veeranki O L, Tong Z M, Dokey R, et al. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. Oncotarget, 2019, 10(45): 4703-4718.
doi: 10.18632/oncotarget.27095
pmid: 31384397
|
[88] |
Su D, Zhang D D, Jin J Y, et al. Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma. Nature Communications, 2019, 10: 5076.
doi: 10.1038/s41467-019-12846-7
|
[89] |
Liu F F, Zu X Y, Xie X M, et al. Ethyl gallate as a novel ERK1/ 2 inhibitor suppresses patient-derived esophageal tumor growth. Molecular Carcinogenesis, 2019, 58(4): 533-543.
doi: 10.1002/mc.22948
|
[90] |
Wang Z Q, da Silva T G, Jin K, et al. Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. Cancer Research, 2014, 74(21): 6364-6374.
doi: 10.1158/0008-5472.CAN-14-2051
|
[91] |
Xuan Y J, Sheng Y Q, Zhang D Q, et al. Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models. Translational Oncology, 2021, 14(8): 101138.
doi: 10.1016/j.tranon.2021.101138
|
[92] |
Hu Y M, Liu F F, Jia X C, et al. Periplogenin suppresses the growth of esophageal squamous cell carcinoma in vitro and in vivo by targeting STAT3. Oncogene, 2021, 40(23): 3942-3958.
doi: 10.1038/s41388-021-01817-2
|
[93] |
Bao Z, Li A, Lu X B, et al. Oxethazaine inhibits esophageal squamous cell carcinoma proliferation and metastasis by targeting aurora kinase A. Cell Death & Disease, 2022, 13: 189.
|
[94] |
Xing H, Gao M S, Wang Y X, et al. Genome-wide gain-of-function screening identifies EZH 2 mediating resistance to PI3Kα inhibitors in oesophageal squamous cell carcinoma. Clinical and Translational Medicine, 2022, 12(5): e835.
|
[95] |
Shi J H, Li Y Y, Jia R B, et al. The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance. International Journal of Cancer, 2020, 146(8): 2078-2088.
doi: 10.1002/ijc.32662
|
[96] |
Miao J X, Wang J Y, Li H Z, et al. Promising xenograft animal model recapitulating the features of human pancreatic cancer. World Journal of Gastroenterology, 2020, 26(32): 4802-4816.
doi: 10.3748/wjg.v26.i32.4802
|
[97] |
宋松, 祝献民, 范国平. 免疫缺陷大鼠模型的研究进展. 自然杂志, 2021, 43(5): 365-373.
|
|
Song S, Zhu X M, Fan G P. Recent progress in development of immunodeficient rat models. Chinese Journal of Nature, 2021, 43(5): 365-373.
|
[98] |
Lynch M, Ackerman M S, Gout J F, et al. Genetic drift, selection and the evolution of the mutation rate. Nature Reviews Genetics, 2016, 17(11): 704-714.
doi: 10.1038/nrg.2016.104
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|